Clinical Trials Browser

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04512534 2026-04-02

Sincerely20

Phase 2 Recruiting

51 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06519526 2026-03-24

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Recruiting

25 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06630091 2026-02-17

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2 Recruiting

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Recruiting

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06160843 2025-09-05

POLAR

Phase 2 Recruiting

24 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Phase 2 Recruiting

115 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

32 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2 Recruiting

33 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT06151106 2025-02-19

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Phase 2 Recruiting

33 enrolled

Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase 2 Recruiting

37 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06468267 2024-08-01

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Phase 2 Recruiting

50 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06433362 2024-05-29

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Phase 2 Recruiting

115 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05963347 2023-09-01

Go-CHOP as the Frontline Therapy for PTCL

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04922567 2022-11-07

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 2 Recruiting

289 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Sincerely20

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Amping up With PemJAK

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

POLAR

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Go-CHOP as the Frontline Therapy for PTCL

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma